[Observational survey of the French Urological Association Oncology Committee (CCAFU) evaluating the practice of immediate postoperative instillation (IPOP) using mitomycin C for non-muscle invasive bladder cancer (NMIBC) treatment].. Enquête observationnelle du Comité de cancérologie de l’association française d’urologie (CCAFU) sur la pratique des instillations postopératoires précoces (IPOP) de mitomycine C pour le traitement des tumeurs de vessie n’infiltrant pas le muscle (TVNIM)

Archive ouverte

Neuzillet, Y. | Colin, P. | Comperat, E. | Dubosq, F. | Houédé, N. | Larre, S. | Masson-Lecomte, A. | Pignot, G. | Puech, Pascal | Roumiguié, M. | Xylinas, E. | Mejean, A. | Roupret, M.

Edité par CCSD ; Elsevier Masson -

International audience. OBJECTIVE:To evaluate the practice of immediate postoperative instillation (IPOP) using mitomycin C for non-muscle invasive bladder cancer (NMIBC) treatment by urologists members of the French Association of Urology (AFU).MATERIAL AND METHOD:Internet-based observational survey evaluating indications and practical modalities of IPOP in NMIBC treatment using questionnaire sent in May 2014 to 915 urologists.RESULTS:Two hundred ninety-eight urologists participated in the survey (response rate: 32.6%) and 57% prescribed the IPOP. The median frequency of IPOP prescription was 3.3%, and was higher in the academic public sector. The CASE recommendations were self-assessed as known or well-known in 67% of cases. The selections criteria for IPOP were adequately identified by 62% of urologists, without differences according to sectors of activity. The IPOP prescription modalities were declared as an obstacle to the completion for 41.9% of urologists, and especially in the private sector. Completion times of IPOP were declared <24h in 91% of cases. We see that 28.5% of urologists prescribed an urinary alkalization. The average frequency of complications of IPOP was 0.91 per urologist.CONCLUSIONS:The IPOP prescription frequency was higher among urologists practicing in the academic sector. Neither the level of knowledge of the recommendations nor the frequency of complications of IPOP had explained this difference. However, the prescription modalities were more frequently reported as an obstacle to their completion in the private sector.LEVEL OF EVIDENCE:3.

Consulter en ligne

Suggestions

Du même auteur

[Molecular, preclinical, and clinical comparative data regarding different strains of bacillus Calmette-Guérin (BCG): Review by the French Urological Association Oncology Committee (CCAFU)].. Données comparatives moléculaires, précliniques et cliniques des différentes souches de bacille de Calmette-Guérin (BCG) : revue de la littérature du Comité de cancérologie de l’Association française d’urologie (CCAFU)

Archive ouverte | Neuzillet, Y. | CCSD

International audience. OBJECTIVE:To review the differences between the BCG strains used for the treatment of non-muscle invasive bladder cancer (NMIBC) at the molecular level, regarding cytotoxicity, immunogenicity...

[CCAFU french national guidelines 2016-2018 on upper tract tumors].. Recommandations en onco-urologie 2016-2018 du CCAFU : Tumeurs de la voie excrétrice supérieure

Archive ouverte | Rouprêt, M. | CCSD

International audience. The purpose was to propose an update of the french guidelines from the national committee CCAFU on upper tract urothelial carcinomas (UTUC).

[CCAFU french national guidelines 2016-2018 on bladder cancer].

Archive ouverte | Rouprêt, M. | CCSD

International audience. OBJECTIVE:The purpose of the guidelines national committee CCAFU on bladder cancer was to propose updated french guidelines for non-muscle invasive (NMIBC) and invasive (MIBC) bladder cancers...

Chargement des enrichissements...